X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TORRENT PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TORRENT PHARMA DR. REDDYS LAB/
TORRENT PHARMA
 
P/E (TTM) x 31.5 44.8 70.4% View Chart
P/BV x 3.4 6.3 53.4% View Chart
Dividend Yield % 0.8 0.8 96.3%  

Financials

 DR. REDDYS LAB   TORRENT PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
TORRENT PHARMA
Mar-18
DR. REDDYS LAB/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7881,550 179.9%   
Low Rs1,9021,144 166.3%   
Sales per share (Unadj.) Rs860.8354.7 242.7%  
Earnings per share (Unadj.) Rs57.140.1 142.4%  
Cash flow per share (Unadj.) Rs122.064.2 190.0%  
Dividends per share (Unadj.) Rs20.0014.00 142.9%  
Dividend yield (eoy) %0.91.0 82.0%  
Book value per share (Unadj.) Rs757.7273.1 277.4%  
Shares outstanding (eoy) m165.91169.22 98.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.73.8 71.7%   
Avg P/E ratio x41.133.6 122.3%  
P/CF ratio (eoy) x19.221.0 91.7%  
Price / Book Value ratio x3.14.9 62.8%  
Dividend payout %35.034.9 100.3%   
Avg Mkt Cap Rs m389,034227,897 170.7%   
No. of employees `00023.514.7 160.0%   
Total wages/salary Rs m32,14911,353 283.2%   
Avg. sales/employee Rs Th6,070.84,083.0 148.7%   
Avg. wages/employee Rs Th1,366.6772.3 177.0%   
Avg. net profit/employee Rs Th402.5461.3 87.2%   
INCOME DATA
Net Sales Rs m142,81060,021 237.9%  
Other income Rs m1,5522,988 51.9%   
Total revenues Rs m144,36263,009 229.1%   
Gross profit Rs m23,51213,493 174.3%  
Depreciation Rs m10,7724,086 263.6%   
Interest Rs m7883,085 25.5%   
Profit before tax Rs m13,5049,310 145.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3802,529 173.2%   
Profit after tax Rs m9,4686,781 139.6%  
Gross profit margin %16.522.5 73.2%  
Effective tax rate %32.427.2 119.4%   
Net profit margin %6.611.3 58.7%  
BALANCE SHEET DATA
Current assets Rs m104,98452,623 199.5%   
Current liabilities Rs m68,93852,022 132.5%   
Net working cap to sales %25.21.0 2,518.6%  
Current ratio x1.51.0 150.5%  
Inventory Days Days74120 62.2%  
Debtors Days Days10476 135.9%  
Net fixed assets Rs m104,38585,016 122.8%   
Share capital Rs m830846 98.1%   
"Free" reserves Rs m124,88645,376 275.2%   
Net worth Rs m125,71646,222 272.0%   
Long term debt Rs m25,08941,115 61.0%   
Total assets Rs m225,443142,432 158.3%  
Interest coverage x18.14.0 451.4%   
Debt to equity ratio x0.20.9 22.4%  
Sales to assets ratio x0.60.4 150.3%   
Return on assets %4.56.9 65.7%  
Return on equity %7.514.7 51.3%  
Return on capital %9.714.2 68.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62314,580 498.1%   
Fx outflow Rs m18,9163,600 525.5%   
Net fx Rs m53,70710,980 489.1%   
CASH FLOW
From Operations Rs m18,0308,942 201.6%  
From Investments Rs m-14,883-47,070 31.6%  
From Financial Activity Rs m-4,44034,174 -13.0%  
Net Cashflow Rs m-1,236-3,655 33.8%  

Share Holding

Indian Promoters % 25.5 71.5 35.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 7.0 76.9%  
FIIs % 35.3 12.6 280.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 8.8 173.9%  
Shareholders   75,885 26,511 286.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DR. REDDYS LAB at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

DR. REDDYS LAB share price has hit a 52-week high. It is presently trading at Rs 2,667. BSE 500 Index is up by 0.8% at 15,275. Within the BSE 500, DR. REDDYS LAB (up 2.4%) and SCHNEIDER ELECTRIC INFRA (up 5.9%) are among the top gainers, while top losers are YES BANK and GODREJ PROPERTIES.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - SHASUN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS